The company's lead product candidate, INZ-701, is an enzyme replacement therapy designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies, providing the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), two phenotypes of ENPP1 Deficiency, potentially offering disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism.